IN8bio, Inc. (INAB)

NASDAQ: INAB · Real-Time Price · USD

0.1780

-0.0113 (-5.97%)

At close: Apr 28, 2025, 4:00 PM

0.1760

-0.0020 (-1.12%)

Pre-market: Apr 29, 2025, 4:01 AM EDT

IN8bio Employees

IN8bio had 18 employees as of December 31, 2024. The number of employees decreased by 13 or -41.94% compared to the previous year.

Employees

18

Change (1Y)

-13

Growth (1Y)

-41.94%

Revenue / Employee

n/a

Profits / Employee

-$1,690,944

Market Cap

14.46M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	18	-13	-41.94%
Dec 31, 2023	31	5	19.23%
Dec 31, 2022	26	7	36.84%
Dec 31, 2021	19	5	35.71%
Dec 31, 2020	14	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

INAB News

20 hours ago - IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025 - GlobeNewsWire
4 weeks ago - IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025 - GlobeNewsWire
5 weeks ago - IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025 - GlobeNewsWire
6 weeks ago - IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
2 months ago - IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases - GlobeNewsWire
2 months ago - IN8bio to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
2 months ago - IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewsWire
2 months ago - IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - GlobeNewsWire